logo-loader
viewIQ-AI Limited

IQ-AI’s Imaging Biometrics subsidiary wins US$2.75mln grant from US government

The grant provides Imaging Biometrics with income for five years, money which it will use to further develop its brain tumour software

IQ-AI Limited - IQ-AI’s Imaging Biometrics subsidiary wins US$2.75mln grant from US government

IQ-AI Limited’s (LON:IQAI) Imaging Biometrics subsidiary has received a US$2.75mln, five-year grant from the US Department of Health’s National Cancer Institute.

Imaging Biometrics will use the money to develop more software solutions that can help doctors better understand and treat advanced brain tumours.

READ: IB working on technologies that lessen reliance on potentially harmful chemicals

Its Rad Tech software was used last year in a big US clinical trial to quantify how patients were responding to Avastin – a common cancer medication.

“Our grant and contract development work are important stimuli at Imaging Biometrics,” said IB’s chief executive David Smith.

“This grant will provide income for the company for the next five years, as well as, further catalyse the development of our quantitative imaging tools, enabling us to apply the result of this collaboration with MCW to our commercial products.”

IQ-AI shares were up 7.8% to 6.25p on Wednesday morning, valuing the company at £8.4mln.

Quick facts: IQ-AI Limited

Price: 4.15 GBX

LSE:IQAI
Market: LSE
Market Cap: £5.84 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of IQ-AI Limited named herein, including the promotion by the Company of IQ-AI Limited in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: More from Imaging Biometrics on the AI deal

IQ-AI Limited’s (LON:IQAI) subsidiary, Imaging Biometrics (IB) recently signed a global distribution deal for imaging analysis software designed to detect chronic liver disease (CLD) and CEO Mike Schmainda tells Proactive why that's been so significant. Under the agreement with US firm AI...

1 week, 5 days ago

2 min read